Companies TransMedics Group, Inc.
TransMedics (TMDX): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me TransMedics Group, Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers56th pct.Of 17 peer CEOs
CEO pay, last three years
- $6,758,070FY2023
- $8,199,136FY2024
- $10,915,533FY2025
CEO total pay was $10,915,533 in fiscal 2025, up from $8,199,136 in fiscal 2024.
FY2025: salary $776,923 · bonus $0 · stock awards $4,364,013 · option awards $4,360,147
Executives and directors
Gerardo Hernandez · CFOAnil Ranganath · General CounselNicholas Corcoran · SVPTamer Khayal · CCOWaleed Hassanein · CEODavid Weill · Independent DirectorEdward M. Basile · Independent DirectorEdwin M. Kania, Jr · Independent DirectorJames R. Tobin · Chair of the BoardMerilee Raines · Independent DirectorStephanie Lovell · Independent DirectorThomas J. Gunderson · Independent Director
Frequently asked questions
Who was the highest-paid executive at TransMedics Group, Inc. in fiscal 2025?
As disclosed, Waleed Hassanein (President and Chief Executive Officer) was the highest-paid executive at TransMedics Group, Inc. in fiscal 2025, with total compensation of $10,915,533.
How does TransMedics Group, Inc.'s chief executive pay compare to its disclosed peer group?
As disclosed, Waleed Hassanein's total compensation ranked at the 56th percentile of TransMedics Group, Inc.'s disclosed peer group.
What is TransMedics Group, Inc.'s CEO-to-median employee pay ratio?
As disclosed, TransMedics Group, Inc.'s CEO-to-median employee pay ratio was 86:1.
How did shareholders vote on TransMedics Group, Inc.'s executive compensation?
As disclosed, 95.17% of shareholders supported TransMedics Group, Inc.'s executive compensation in the latest say-on-pay vote.
How much does TransMedics Group, Inc. spend in total on board compensation for fiscal 2025?
As disclosed, TransMedics Group, Inc. reported total board compensation of $2,449,823 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Waleed Hassanein | $776,923 | $0 | $4,364,013 | $4,360,147 | $1,400,000 | $0 | $14,450 | $10,915,533 |
| President and Chief Executive Officer | ||||||||
| Tamer Khayal | 496,316 | 0 | 1,357,775 | 1,355,805 | 525,798 | 0 | 14,450 | 3,750,144 |
| Former Chief Commercial Officer | ||||||||
| Nicholas Corcoran | 451,731 | 0 | 977,573 | 976,166 | 399,656 | 0 | 14,450 | 2,819,576 |
| Senior Vice President of Supply Chain and Operations | ||||||||
| Gerardo Hernandez | 488,462 | 0 | 271,540 | 271,120 | 525,000 | 0 | 14,450 | 1,570,572 |
| Chief Financial Officer | ||||||||
| Anil Ranganath | 412,308 | 0 | 434,494 | 433,823 | 208,000 | 0 | 14,450 | 1,503,075 |
| Former Senior Vice President, General Counsel and Corporate Secretary | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Waleed Hassanein | $10,915,533 | $8,199,136 | $6,758,070 | ↑ +2,716,397 |
| Tamer Khayal | 3,750,144 | 3,077,769 | 2,630,508 | ↑ +672,375 |
| Nicholas Corcoran | 2,819,576 | 2,724,567 | 2,517,432 | ↑ +95,009 |
| Gerardo Hernandez | 1,570,572 | 1,757,472 | — | ↓ −186,900 |
| Anil Ranganath | 1,503,075 | 594,250 | 2,187,342 | ↑ +908,825 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
To accomplish our business and growth objectives, we must be able to attract and retain talented executives whose skills and experience enable them to contribute to our long-term success. To that end, the philosophy and principal objectives of our executive compensation program are to attract, fairly compensate, appropriately incentivize, and retain superior executive talent in a manner that aligns their long-term interests with those of our shareholders.
| CEO STI target (% of salary) | 100% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Pearl Meyer |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | True |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Waleed Hassanein | OPTION | 2025-02-25 | — | — | 90,185 | — | $4,360,147 |
| Anil Ranganath | RSU | 2025-02-24 | — | — | 5,634 | — | 434,494 |
| Tamer Khayal | RSU | 2025-02-24 | — | — | 17,606 | — | 1,357,775 |
| Gerardo Hernandez | RSU | 2025-02-24 | — | — | 3,521 | — | 271,540 |
| Anil Ranganath | OPTION | 2025-02-24 | — | — | 8,479 | — | 433,823 |
| Waleed Hassanein | RSU | 2025-02-25 | — | — | 59,781 | — | 4,364,013 |
| Nicholas Corcoran | RSU | 2025-02-24 | — | — | 12,676 | — | 977,573 |
| Gerardo Hernandez | OPTION | 2025-02-24 | — | — | 5,299 | — | 271,120 |
| Tamer Khayal | OPTION | 2025-02-24 | — | — | 26,499 | — | 1,355,805 |
| Nicholas Corcoran | OPTION | 2025-02-24 | — | — | 19,079 | — | 976,166 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Waleed Hassanein | $4,364,013 | $0 | $4,360,147 | 0.0% |
| Anil Ranganath | 434,494 | 0 | 433,823 | 0.0% |
| Tamer Khayal | 1,357,775 | 0 | 1,355,805 | 0.0% |
| Gerardo Hernandez | 271,540 | 0 | 271,120 | 0.0% |
| Nicholas Corcoran | 977,573 | 0 | 976,166 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Tamer Khayal | Option | 2,167 | 13.28 | — |
| Gerardo Hernandez | RSU | 3,521 | — | 428,330 |
| Gerardo Hernandez | Option | 4,196 | 77.12 | — |
| Tamer Khayal | RSU | 4,358 | — | 530,151 |
| Anil Ranganath | RSU | 4,756 | — | 578,567 |
| Nicholas Corcoran | Option | 5,345 | 66.1 | — |
| Anil Ranganath | Option | 5,517 | 93.88 | — |
| Anil Ranganath | RSU | 5,634 | — | 685,376 |
| Tamer Khayal | Option | 5,841 | 66.1 | — |
| Nicholas Corcoran | RSU | 6,442 | — | 783,669 |
| Anil Ranganath | Option | 6,714 | 77.12 | — |
| Nicholas Corcoran | RSU | 7,627 | — | 927,825 |
| Tamer Khayal | RSU | 8,084 | — | 983,419 |
| Gerardo Hernandez | RSU | 9,347 | — | 1,137,063 |
| Nicholas Corcoran | Option | 9,551 | 83.14 | — |
| Tamer Khayal | Option | 10,125 | 83.14 | — |
| Waleed Hassanein | Option | 10,417 | 13.28 | — |
| Waleed Hassanein | RSU | 12,444 | — | 1,513,813 |
| Nicholas Corcoran | RSU | 12,676 | — | 1,542,035 |
| Gerardo Hernandez | Option | 14,192 | 69.84 | — |
| Nicholas Corcoran | Option | 15,105 | 77.12 | — |
| Waleed Hassanein | Option | 16,674 | 66.1 | — |
| Tamer Khayal | RSU | 17,606 | — | 2,141,770 |
| Tamer Khayal | Option | 20,979 | 77.12 | — |
| Waleed Hassanein | RSU | 24,503 | — | 2,980,790 |
| Waleed Hassanein | Option | 30,684 | 83.14 | — |
| Waleed Hassanein | RSU | 59,781 | — | 7,272,359 |
| Waleed Hassanein | Option | 71,397 | 73 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| James R. TobinIndependent · Board Chair · Nominating/Governance | $136,000 | $263,208 | $0 | $0 | — | $399,208 |
| Thomas J. GundersonIndependent · Audit · Compensation (Chair) | 85,000 | 263,208 | 0 | 0 | 6,564 | 354,772 |
| Merilee RainesIndependent · Audit (Chair) · Compensation | 90,000 | 263,208 | 0 | 0 | 960 | 354,168 |
| Edward M. BasileIndependent · Audit · Nominating/Governance (Chair) | 80,000 | 263,208 | 0 | 0 | 1,843 | 345,050 |
| David WeillIndependent · Compensation · Nominating/Governance | 71,000 | 263,208 | 0 | 0 | — | 334,208 |
| Stephanie LovellIndependent · Compensation · Nominating/Governance | 71,000 | 263,208 | 0 | 0 | — | 334,208 |
| Edwin M. Kania, JrIndependent · Audit | 65,000 | 263,208 | 0 | 0 | — | 328,208 |
| Waleed H. HassaneinEmployee director | 0 | 0 | 0 | — | 0 | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $55,000 |
|---|---|
| Annual equity retainer | $225,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 25,000 / 20,000 / 15,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $598,000 |
| Equity awards (grant-date value) | $1,842,456 |
| All other compensation | $9,367 |
| Total cost of the board | $2,449,823 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names TransMedics as a peer
Companies that benchmark against TMDX
11 companies name TMDX as a compensation peer
The list of companies that name TMDX as a peer is temporarily unavailable — recheck shortly.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
RGEN Repligen CorporationATRC AtriCure, Inc.GKOS Glaukos CorporationSTAA STAAR Surgical CompanyAZTA Azenta, Inc.TNDM Tandem Diabetes Care, Inc.TECH Bio-Techne CorporationINSM Insmed IncorporatedPRCT PROCEPT BioRoboticsPODD Insulet CorporationHAE Haemonetics CorporationINSP Inspire Medical Systems,NVCR NovoCure LimitedAPLS Apellis Pharmaceuticals, Inc.AXNX Axonics, Inc.NARI Inari Medical, Inc.SWAV Shockwave Medical, Inc.
Peer reciprocity
The companies TransMedics Group, Inc. names as compensation peers that name it back in their own disclosed peer groups.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Insulet Corporation | 2025 | Ashley McEvoy | $729,808 | $12,958,850 | $2,999,913 | $2,031,562 | $18,858,968 |
| 2 | Procept BioRobotics | 2025 | Larry Wood | 304,830 | 7,217,251 | 7,226,599 | 243,864 | 16,783,853 |
| 3 | Insmed Incorporated | 2025 | William Lewis | 854,550 | 2,999,940 | 9,000,033 | 1,495,463 | 14,467,393 |
| 4 | NovoCure Limited | 2025 | Ashley Cordova | 901,837 | 8,249,965 | 2,752,814 | 811,653 | 13,198,354 |
| 5 | Haemonetics Corporation | 2026 | Christopher Simon | 1,100,008 | 7,561,987 | 1,504,968 | 1,834,250 | 12,044,701 |
| 6 | Glaukos Corporation | 2025 | Thomas Burns | 850,000 | 7,649,947 | 3,527,497 | 0 | 12,034,087 |
| 7 | Apellis Pharmaceuticals, Inc. | 2024 | Cedric Francois | 793,193 | 4,779,832 | 4,787,768 | 0 | 10,957,451 |
| 8 | TransMedics Group, Inc. | 2025 | Waleed Hassanein | 776,923 | 4,364,013 | 4,360,147 | 1,400,000 | 10,915,533 |
| 9 | Azenta, Inc. | 2025 | John Marotta | 900,000 | 8,386,297 | 0 | 1,063,656 | 10,371,414 |
| 10 | AtriCure, Inc. | 2025 | Michael Carrel | 828,439 | 7,203,478 | 0 | 1,171,703 | 9,217,620 |
| 11 | Shockwave Medical, Inc. | 2022 | Doug Godshall | 644,231 | 6,845,660 | 0 | 923,650 | 8,418,871 |
| 12 | Bio-Techne Corporation | 2025 | Kim Kelderman | 936,000 | 3,929,942 | 1,932,848 | 1,318,917 | 8,151,181 |
| 13 | Inspire Medical Systems, | 2025 | Timothy Herbert | 750,572 | 5,999,655 | 0 | 961,557 | 7,711,784 |
| 14 | Staar Surgical Company | 2025 | Stephen Farrell | 580,000 | 6,836,000 | 0 | 0 | 7,522,385 |
| 15 | Tandem Diabetes Care, Inc. | 2025 | John Sheridan | 790,583 | 5,367,796 | 0 | 674,090 | 6,858,503 |
| 16 | Repligen Corporation | 2025 | Olivier Loeillot | 860,000 | 3,374,853 | 1,095,626 | 774,000 | 6,114,771 |
| 17 | Inari Medical, Inc. | 2023 | Andrew Hykes | 700,000 | 2,606,744 | 937,488 | 826,000 | 5,083,365 |
| — | Axonics, Inc. | — | — | — | — | — | — | not in coverage universe |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| TransMedics Group, Inc. | 175% | Options 50 · RSU 50 | not disclosed | Pearl Meyer |
| Apellis Pharmaceuticals, Inc. | 90.74% | RSU 50 · PSU 50 | not disclosed | Pay Governance |
| AtriCure, Inc. | not disclosed | PSU 70 · RSU 30 | No | Korn Ferry |
| Axonics, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
| Azenta, Inc. | not disclosed | PSU 50 · RSU 50 | Yes — Relative TSR (rTSR) | Pearl Meyer |
| Bio-Techne Corporation | 128.1% | PSU 50 · Options 25 · RSU 25 | No | Aon |
| Glaukos Corporation | not disclosed | RSU 50 · PRSU 50 | No | Frederic W. Cook & Co., Inc. |
| Haemonetics Corporation | 133.4% | PSU 60 · RSU 20 · Options 20 | Yes — Relative Total Shareholder Return (rTSR) | Pearl Meyer & Partners, LLC |
| Inari Medical, Inc. | 118% | RSU 75 · Option 25 | not disclosed | FW Cook |
| Insmed Incorporated | 175% | Options 75 · RSU 25 | No | Willis Towers Watson (WTW) |
| Inspire Medical Systems, | 111.4% | PSU 50 · RSU 50 | No | Aon |
| Insulet Corporation | 195.8% | PSU 60 · RSU 20 · Options 20 | No | Pearl Meyer & Partners, LLC |
| NovoCure Limited | 100% | PSU 50 · RSU 25 · Options 25 | No | Frederic W. Cook & Co., Inc. |
| Procept BioRobotics | 80% | RSU 50 · PSU 25 · Options 25 | Yes — Relative TSR | Alpine |
| Repligen Corporation | 100% | RSU 50 · PSU 25 · Options 25 | No | Meridian Compensation Partners, LLC |
| Shockwave Medical, Inc. | 142.1% | RSU 50 · PRSU 50 | No | Compensia |
| Staar Surgical Company | 135% | RSU 50 · PSU 50 | No | Semler Brossy |
| Tandem Diabetes Care, Inc. | 87% | PSU 50 · RSU 50 | Yes — TSR performance compared to the Russell 3000 index in the three-year period between 2025 and 2027 | WTW |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-05-20 | 22,871,647 | 1,161,181 | 30,895 | 95.17% | Passed |
| 2025 | 2025-05-22 | 20,883,760 | 755,962 | 54,519 | 96.51% | Passed |
| 2024 | 2024-05-23 | 22,902,359 | 1,321,627 | 16,949 | 94.54% | Passed |
| 2023 | 2023-05-25 | 22,963,086 | 1,519,849 | 18,275 | 93.79% | Passed |
| 2022 | 2022-06-01 | 7,542,657 | 10,404,369 | 19,309 | 42.03% | Failed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-05-20 | 95.17%a |
| 2025 | 2025-05-22 | 96.51%b |
| 2024 | 2024-05-23 | 94.54%c |
a. Approved under the standard stated in the filing — “Broker non-votes and abstentions will have no effect on the outcome of each proposal.”.
b. Approved under the standard stated in the filing — “Broker non-votes and abstentions will have no effect on the outcome of each proposal.”.
c. Approved under the standard stated in the filing — “Broker non-votes and abstentions will have no effect on the outcome of each proposal.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 86 : 1 |
|---|---|
| CEO total compensation | $10,915,533 |
| Median employee compensation | $127,304 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Matthew S. Forsyth | See Remarks | 2026-05-19 | A | 23,171 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Matthew S. Forsyth | See Remarks | 2026-05-19 | A | 15,409 | 0 | 0 | Common | Form 4 ↗ |
| Edward M. Basile | Director | 2026-05-20 | A | 2,922 | 0 | 0 | Common | Form 4 ↗ |
| Thomas J. Gunderson | Director | 2026-05-20 | A | 2,922 | 0 | 0 | Common | Form 4 ↗ |
| Edwin M. Kania, Jr | Director | 2026-05-20 | A | 2,922 | 0 | 0 | Common | Form 4 ↗ |
| James R. Tobin | Director | 2026-05-20 | A | 2,922 | 0 | 0 | Common | Form 4 ↗ |
| David Weill | Director | 2026-05-20 | A | 2,922 | 0 | 0 | Common | Form 4 ↗ |
| Stephanie Lovell | Director | 2026-05-20 | A | 2,922 | 0 | 0 | Common | Form 4 ↗ |
| Merilee Raines | Director | 2026-05-20 | A | 2,922 | 0 | 0 | Common | Form 4 ↗ |
| Thomas J. Gunderson | Director | 2026-06-15 | A | 19,285 | 2 | 42,620 | Common | Form 4 ↗ |
| Thomas J. Gunderson | Director | 2026-06-15 | D | 19,285 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Thomas J. Gunderson | Director | 2026-06-15 | D | 9,624 | 75 | 722,377 | Common | Form 4 ↗ |
| Nicholas Corcoran | See remarks | 2026-07-10 | A | 11,727 | 0 | 0 | Common | Form 4 ↗ |
| Waleed H. Hassanein | Director | 2026-07-10 | A | 112,984 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Waleed H. Hassanein | Director | 2026-07-10 | A | 49,669 | 0 | 0 | Common | Form 4 ↗ |
| Gerardo Hernandez | Chief Financial Officer | 2026-07-10 | A | 26,153 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Nicholas Corcoran | See remarks | 2026-07-10 | A | 17,784 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gerardo Hernandez | Chief Financial Officer | 2026-07-10 | A | 17,246 | 0 | 0 | Common | Form 4 ↗ |
| James R. Tobin | Director | 2026-08-17 | D | 18,000 | 0 | 0 | Common | Form 4 ↗ |
| David Weill | Director | 2026-09-11 | A | 1,336 | 82 | 109,058 | Common | Form 4 ↗ |
| Fernando N. Araujo | See Remarks | 2026-10-28 | A | 34,419 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Fernando N. Araujo | See Remarks | 2026-10-28 | A | 22,969 | 0 | 0 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (70 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Waleed Hassanein. DEF 14A, filed 2026-04-10. Section “Summary Compensation Table” · page 37. As printed: 10,915,533. View filing ↗
- Section 01, Tamer Khayal. DEF 14A, filed 2026-04-10. Section “Summary Compensation Table”. As printed: 3,750,144. View filing ↗
- Section 01, Nicholas Corcoran. DEF 14A, filed 2026-04-10. Section “Summary Compensation Table”. As printed: 2,819,576. View filing ↗
- Section 01, Gerardo Hernandez. DEF 14A, filed 2026-04-10. Section “Summary Compensation Table”. As printed: 1,570,572. View filing ↗
- Section 01, Anil Ranganath. DEF 14A, filed 2026-04-10. Section “Summary Compensation Table”. As printed: 1,503,075. View filing ↗
- Section 03, Waleed Hassanein OPTION. DEF 14A, filed 2026-04-10. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Anil Ranganath RSU. DEF 14A, filed 2026-04-10. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Tamer Khayal RSU. DEF 14A, filed 2026-04-10. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Gerardo Hernandez RSU. DEF 14A, filed 2026-04-10. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Anil Ranganath OPTION. DEF 14A, filed 2026-04-10. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Waleed Hassanein RSU. DEF 14A, filed 2026-04-10. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Nicholas Corcoran RSU. DEF 14A, filed 2026-04-10. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Gerardo Hernandez OPTION. DEF 14A, filed 2026-04-10. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Tamer Khayal OPTION. DEF 14A, filed 2026-04-10. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Nicholas Corcoran OPTION. DEF 14A, filed 2026-04-10. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2026-04-10. Section “CEO Pay Ratio”. As printed: 86 : 1. View filing ↗
- Section 08, James R. Tobin. DEF 14A, filed 2026-04-10. Section “Director Compensation”. As printed: 399,208. View filing ↗
- Section 08, Thomas J. Gunderson. DEF 14A, filed 2026-04-10. Section “Director Compensation”. As printed: 354,772. View filing ↗
- Section 08, Merilee Raines. DEF 14A, filed 2026-04-10. Section “Director Compensation”. As printed: 354,168. View filing ↗
- Section 08, Edward M. Basile. DEF 14A, filed 2026-04-10. Section “Director Compensation”. As printed: 345,050. View filing ↗
- Section 08, David Weill. DEF 14A, filed 2026-04-10. Section “Director Compensation”. As printed: 334,208. View filing ↗
- Section 08, Stephanie Lovell. DEF 14A, filed 2026-04-10. Section “Director Compensation”. As printed: 334,208. View filing ↗
- Section 08, Edwin M. Kania, Jr. DEF 14A, filed 2026-04-10. Section “Director Compensation”. As printed: 328,208. View filing ↗
- Section 08, Waleed H. Hassanein. DEF 14A, filed 2026-04-10. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Matthew S. Forsyth 2026-05-19. Form 4, filed 2026-05-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Matthew S. Forsyth 2026-05-19. Form 4, filed 2026-05-21. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Edward M. Basile 2026-05-20. Form 4, filed 2026-05-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas J. Gunderson 2026-05-20. Form 4, filed 2026-05-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Edwin M. Kania, Jr 2026-05-20. Form 4, filed 2026-05-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James R. Tobin 2026-05-20. Form 4, filed 2026-05-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Weill 2026-05-20. Form 4, filed 2026-05-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Stephanie Lovell 2026-05-20. Form 4, filed 2026-05-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Merilee Raines 2026-05-20. Form 4, filed 2026-05-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas J. Gunderson 2026-06-15. Form 4, filed 2026-06-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas J. Gunderson 2026-06-15. Form 4, filed 2026-06-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Thomas J. Gunderson 2026-06-15. Form 4, filed 2026-06-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nicholas Corcoran 2026-07-10. Form 4, filed 2026-07-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Waleed H. Hassanein 2026-07-10. Form 4, filed 2026-07-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Waleed H. Hassanein 2026-07-10. Form 4, filed 2026-07-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gerardo Hernandez 2026-07-10. Form 4, filed 2026-07-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nicholas Corcoran 2026-07-10. Form 4, filed 2026-07-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gerardo Hernandez 2026-07-10. Form 4, filed 2026-07-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James R. Tobin 2026-08-17. Form 4, filed 2026-08-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, David Weill 2026-09-11. Form 4, filed 2026-09-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Fernando N. Araujo 2026-10-28. Form 4, filed 2026-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Fernando N. Araujo 2026-10-28. Form 4, filed 2026-10-30. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-05-21. Item 5.07 · say-on-pay result. As reported: 95.17% (votes for as printed: 22,871,647). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-05-23. Item 5.07 · say-on-pay result. As reported: 96.51% (votes for as printed: 20,883,760). View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-05-28. Item 5.07 · say-on-pay result. As reported: 94.54% (votes for as printed: 22,902,359). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 598,000 + equity 1,842,456 + all other 9,367 = 2,449,823, summed across the director compensation table rows.
- Insulet Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in Insulet Corporation's own proxy. As printed: 18,858,968. View filing ↗
- Procept BioRobotics, Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Procept BioRobotics's own proxy. As printed: 16,783,853. View filing ↗
- Insmed Incorporated, Section 10b CEO total. DEF 14A, filed 2026-04-01. CEO total compensation as printed in Insmed Incorporated's own proxy. As printed: 14,467,393. View filing ↗
- NovoCure Limited, Section 10b CEO total. DEF 14A, filed 2026-04-20. CEO total compensation as printed in NovoCure Limited's own proxy. As printed: 13,198,354. View filing ↗
- Haemonetics Corporation, Section 10b CEO total. DEF 14A, filed 2026-06-09. CEO total compensation as printed in Haemonetics Corporation's own proxy. As printed: 12,044,701. View filing ↗
- Glaukos Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-16. CEO total compensation as printed in Glaukos Corporation's own proxy. As printed: 12,034,087. View filing ↗
- Apellis Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-23. CEO total compensation as printed in Apellis Pharmaceuticals, Inc.'s own proxy. As printed: 10,957,451. View filing ↗
- TransMedics Group, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-10. CEO total compensation as printed in TransMedics Group, Inc.'s own proxy. As printed: 10,915,533. View filing ↗
- Azenta, Inc., Section 10b CEO total. DEF 14A, filed 2025-12-18. CEO total compensation as printed in Azenta, Inc.'s own proxy. As printed: 10,371,414. View filing ↗
- AtriCure, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in AtriCure, Inc.'s own proxy. As printed: 9,217,620. View filing ↗
- Shockwave Medical, Inc., Section 10b CEO total. DEF 14A, filed 2023-04-21. CEO total compensation as printed in Shockwave Medical, Inc.'s own proxy. As printed: 8,418,871. View filing ↗
- Bio-Techne Corporation, Section 10b CEO total. DEF 14A, filed 2025-09-19. CEO total compensation as printed in Bio-Techne Corporation's own proxy. As printed: 8,151,181. View filing ↗
- Inspire Medical Systems,, Section 10b CEO total. DEF 14A, filed 2026-03-20. CEO total compensation as printed in Inspire Medical Systems,'s own proxy. As printed: 7,711,784. View filing ↗
- Staar Surgical Company, Section 10b CEO total. DEF 14A, filed 2026-05-04. CEO total compensation as printed in Staar Surgical Company's own proxy. As printed: 7,522,385. View filing ↗
- Tandem Diabetes Care, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-07. CEO total compensation as printed in Tandem Diabetes Care, Inc.'s own proxy. As printed: 6,858,503. View filing ↗
- Repligen Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-02. CEO total compensation as printed in Repligen Corporation's own proxy. As printed: 6,114,771. View filing ↗
- Inari Medical, Inc., Section 10b CEO total. DEF 14A, filed 2024-03-13. CEO total compensation as printed in Inari Medical, Inc.'s own proxy. As printed: 5,083,365. View filing ↗
- Section 10a, Glaukos Corporation reciprocity. DEF 14A. Glaukos Corporation names TransMedics Group, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗